BioVentrix Names Jim Dillon President and CEO | Company & Finance

SAN RAMON, Calif.–(Company WIRE)–Apr 29, 2021–

BioVentrix, Inc., a privately held clinical unit enterprise focused on dealing with congestive coronary heart failure (CHF) via Transcatheter-dependent Ventricular Restoration (TCVR), currently introduced that Jim Dillon has been named President and CEO. In his function, Mr. Dillon will be developing BioVentrix into a significant-performance coronary heart failure therapy corporation, top the team towards the accomplishment of its mission when assembly or exceeding its annual enterprise goals.

BioVentrix President and CEO Jim Dillon (Photograph: Enterprise Wire)

Mr. Dillon is an knowledgeable leader in both equally main cardiovascular businesses and promising start out-up providers. He most not too long ago co-founded Reprieve Cardiovascular and led the company’s funding and improvement of a very distinctive remedy for acute decompensated heart failure (ADHF). Mr. Dillon’s occupation concentrate in coronary heart failure has incorporated establishing therapies to allow native coronary heart restoration, decrease the dimension of a patient’s myocardial infarction, restore grownup and congenital cardiac flaws, and innovate personalized volume administration for acutely decompensated clients.

Mr. Dillon joined St. Jude Health-related in 2011 and held a series of company strategic and profits leadership positions. He was involved with various hugely profitable health care product organizations as a critical contributor to their acquisition and exit. Prior to joining St. Jude, Jim held senior executive gross sales and marketing positions with such businesses as Abiomed, TherOx and InfraReDx.

“Jim’s subject-primarily based leadership model, blended with his verified achievement in setting up higher-performance world-wide groups, tends to make him the ideal applicant to guide our business,” mentioned Steven Healy, Chairman of the Board, BioVentrix. “Jim’s awareness and experience in market improvement, capacity to be certain a business’s financial integrity, and his solid relationships with renowned doctors will prove really helpful in developing BioVentrix and optimizing shareholder worth. I would also like to thank Ken Miller for his yrs of company and numerous contributions to BioVentrix.”

“I am excited to join the BioVentrix team at a pivotal time in the company’s growth,” stated Mr. Dillon. “This is a exclusive opportunity to revolutionize the cure of congestive heart failure brought on by ischemic cardiomyopathy and supply a far better excellent of existence for numerous sufferers worldwide.”

BioVentrix is a privately held health care machine organization headquartered in San Ramon, California (United states of america). BioVentrix’s mission is to boost and expand the treatment accessible for congestive heart failure prompted by ischemic cardiomyopathy (coronary heart muscle illness with lessened blood flow), by means of the progress of fewer invasive, catheter-based mostly techniques.

The Revivent TC™ Program has gained the CE Mark and is commercially obtainable in Europe, in which adoption is expanding. In the U.S., the enterprise is at the moment enrolling individuals in its pivotal demo of the Revivent TC Procedure, the ALIVE Trial.

Speak to: U.S. MEDIA Get hold of

Persistent Communications Inc.

T: (310) 902-1274EU MEDIA Contact

Ammersee Conversation GmbH


Field Key phrase: Overall health Clinical Equipment Surgical procedure OTHER Well being Typical Overall health CARDIOLOGY BIOTECHNOLOGY

Copyright Business Wire 2021.

PUB: 04/29/2021 08:00 AM/DISC: 04/29/2021 08:01 AM

Copyright Enterprise Wire 2021.